Israel Englander Regenxbio Inc. Transaction History

Millennium Management LLC

$192 Billion
Q2 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Regenxbio Inc. stock. As of the latest transaction made, Millennium Management LLC holds 111,949 shares of RGNX stock, worth $906,786. This represents 0.0% of its overall portfolio holdings.

Number of Shares

111,949

Previous 332,829 66.36%

Holding current value

$906,786

Previous $2.38 Million 61.37%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$5.31 - $10.4 $1.17 Million - $2.3 Million	-220,880 Reduced 66.36%	111,949 $919,000
Q1 2025 May 15, 2025	SELL	$5.92 - $8.7 $5.86 Million - $8.61 Million	-989,515 Reduced 74.83%	332,829 $2.38 Million
Q4 2024 Feb 14, 2025	BUY	$7.23 - $11.56 $7.67 Million - $12.3 Million	1,061,187 Added 406.34%	1,322,344 $10.2 Million
Q3 2024 Nov 14, 2024	SELL	$10.49 - $14.39 $475,511 - $652,298	-45,330 Reduced 14.79%	261,157 $2.74 Million
Q2 2024 Aug 14, 2024	BUY	$11.51 - $21.53 $1.62 Million - $3.03 Million	140,666 Added 84.83%	306,487 $3.59 Million
Q1 2024 May 15, 2024	BUY	$12.17 - $24.61 $1.34 Million - $2.72 Million	110,498 Added 199.73%	165,821 $3.49 Million
Q4 2023 Feb 14, 2024	SELL	$12.89 - $20.82 $1.92 Million - $3.1 Million	-149,020 Reduced 72.93%	55,323 $993,000
Q2 2023 Aug 14, 2023	SELL	$17.23 - $21.71 $8.87 Million - $11.2 Million	-514,868 Reduced 71.59%	204,343 $4.08 Million
Q1 2023 May 15, 2023	BUY	$18.08 - $24.55 $12.6 Million - $17.1 Million	697,379 Added 3194.3%	719,211 $13.6 Million
Q4 2022 Feb 14, 2023	BUY	$20.4 - $24.73 $97,695 - $118,431	4,789 Added 28.1%	21,832 $495,000
Q3 2022 Nov 14, 2022	BUY	$22.29 - $35.04 $379,888 - $597,186	17,043 New	17,043 $450,000
Q2 2022 Aug 15, 2022	SELL	$19.35 - $35.04 $4.22 Million - $7.65 Million	-218,316 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$24.62 - $34.31 $4.67 Million - $6.51 Million	189,703 Added 663.0%	218,316 $7.25 Million
Q4 2021 Feb 14, 2022	BUY	$30.19 - $40.28 $677,493 - $903,923	22,441 Added 363.59%	28,613 $936,000
Q3 2021 Nov 15, 2021	SELL	$29.09 - $45.68 $5.5 Million - $8.63 Million	-188,955 Reduced 96.84%	6,172 $259,000
Q2 2021 Aug 16, 2021	SELL	$32.46 - $40.48 $561,363 - $700,061	-17,294 Reduced 8.14%	195,127 $7.58 Million
Q1 2021 May 17, 2021	BUY	$33.61 - $49.95 $6.65 Million - $9.88 Million	197,735 Added 1346.42%	212,421 $7.25 Million
Q4 2020 Feb 16, 2021	BUY	$26.52 - $49.35 $18,988 - $35,334	716 Added 5.13%	14,686 $666,000
Q3 2020 Nov 16, 2020	SELL	$27.01 - $40.26 $3.79 Million - $5.65 Million	-140,374 Reduced 90.95%	13,970 $384,000
Q2 2020 Aug 14, 2020	BUY	$27.75 - $43.44 $4.28 Million - $6.7 Million	154,344 New	154,344 $5.68 Million
Q1 2020 May 14, 2020	SELL	$21.5 - $54.2 $2.27 Million - $5.72 Million	-105,496 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$34.54 - $44.87 $800,084 - $1.04 Million	-23,164 Reduced 18.0%	105,496 $4.32 Million
Q2 2019 Aug 14, 2019	BUY	$42.0 - $59.29 $5.4 Million - $7.63 Million	128,660 New	128,660 $3.95 Million
Q4 2018 Feb 14, 2019	SELL	$39.11 - $75.15 $5.09 Million - $9.79 Million	-130,238 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$65.0 - $82.15 $7.56 Million - $9.56 Million	116,336 Added 836.83%	130,238 $9.83 Million
Q2 2018 Aug 14, 2018	SELL	$27.2 - $74.35 $5.9 Million - $16.1 Million	-216,935 Reduced 93.98%	13,902 $997,000
Q1 2018 May 15, 2018	BUY	$24.05 - $37.5 $3.23 Million - $5.04 Million	134,479 Added 139.56%	230,837 $6.89 Million
Q4 2017 Feb 14, 2018	BUY	$26.0 - $34.6 $2.51 Million - $3.33 Million	96,358	96,358 $3.2 Million

Others Institutions Holding RGNX

# of Institutions

181

Shares Held

45.1M

Call Options Held

103K

Put Options Held

100K

View Full List

About REGENXBIO Inc.

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $350M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

More about RGNX

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account